Detalle Publicación

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

Autores: Dimopoulos, M. (Autor de correspondencia); Weisel, K.; Moreau, P.; Anderson, L. D. ; White, D. ; San Miguel Izquierdo, Jesús; Sonneveld, P. ; Engelhardt, M.; Jenner, M. ; Corso, A.; Durig, J.; Pavic, M.; Salomo, M.; Casal, E.; Srinivasan, S.; Yu, X.; Nguyen, T. V.; Biyukov, T.; Peluso, T. ; Richardson, P.
Título de la revista: LEUKEMIA
ISSN: 0887-6924
Volumen: 35
Número: 6
Páginas: 1722 - 1731
Fecha de publicación: 2021
In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma previously treated with lenalidomide, including those refractory to lenalidomide. This analysis evaluated outcomes in patients at first relapse (N = 226) by lenalidomide-refractory status, prior bortezomib exposure, and prior stem cell transplant (SCT). Second-line PVd significantly improved PFS vs Vd in lenalidomide-refractory (17.8 vs 9.5 months;P = 0.0276) and lenalidomide-nonrefractory patients (22.0 vs 12.0 months;P = 0.0491), patients with prior bortezomib (17.8 vs 12.0 months;P = 0.0068), and patients with (22.0 vs 13.8 months;P = 0.0241) or without (16.5 vs 9.5 months;P = 0.0454) prior SCT. In patients without prior bortezomib, median PFS was 20.7 vs 9.5 months (P = 0.1055). Significant improvement in overall response rate was also observed with PVd vs Vd in lenalidomide-refractory (85.9% vs 50.8%;P < 0.001) and lenalidomide-nonrefractory (95.7% vs 60.0%;P < 0.001) patients, with similar results regardless of prior bortezomib or SCT. No new safety signals were observed. These data demonstrate the benefit of PVd at first relapse, including immediately after upfront lenalidomide treatment failure and other common first-line treatments.